13 research outputs found
Recovery of dialysis patients with COVID-19 : health outcomes 3 months after diagnosis in ERACODA
Background. Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods. We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results. In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8-6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions. Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis
Evaluation of cover-cropping managements on productivity and N-utilization efficiency of kenaf (Hibiscus cannabinus L.), under different nitrogen fertilization rates and soil types
Biomass productivity, nitrogen recovery fraction and nitrogen utilization efficiency (NUE) of kenaf (Hibiscus cannabinus L.) cultivar Tainung 2 were tested, under three Lens culinaries treatments (incorporated, harvested before the sowing of the energy crop and mono-cropping) and four nitrogen dressings (0, 50, 100 and 150 kg ha(-1)), in two field experiments carried out on a fertile, clayey to loamy soil, and on a sandy soil of moderate fertility, in central Greece, over the period 2007-2009. The obtained results showed a positive response in L. culinaries cover cropping on kenaf total yield, on both experimental sites. Total dry biomass fluctuated from 16.07 to 21.46 t ha(-1) for incorporated plots and from 13.63 to 16.55 t ha(-1) for control treatments (relied only on applications of N-fertilization) for sandy soil, and from 14.98 to 19.28 t ha(-1) in case of legume incorporation and from 12.34 to 16.69 t ha(-1) for control plots, for clayey soil, respectively. The evaluated NUE was 76 kg kg(-1), for sandy soil, and 72 kg kg(-1), for clay soil. The recovery fraction escalated from 41% in control plots to 70% in plots with previous L culinaries cultivation for sandy soil, while for clayey soil an increase of 20% was recorded, indicating a prominent effect of legume cover-cropping management. (C) 2012 Elsevier B.V. All rights reserved
BIOMASS PRODUCTION AND N-USE OF FIBRE SORGHUM UNDER DIFFERENT COVER CROPPING MANAGEMENT, NITROGEN INFLUXES AND SOIL TYPES IN CENTRAL GREECE
Field experiments were carried out over a period of three years to evaluate the effect of cover cropping faba bean with fibre sorghum, compared to mono-crop cultivation, on yield (dry matter), nitrogen utilization efficiency (NUE) and N fertilizer recovery fraction of sorghum. Experimental sites were located in central Greece on a fertile, clayey to loamy textured soil, and on a sandy soil of moderate fertility. A factorial combination of four nitrogen application rates (0, 50, 100, 150 kg ha(-1)) and three legume treatments (incorporated into the topsoil or harvested before the sowing of sorghum and mono-cropping) were tested in a split plot design in three blocks. The results showed importance of legume cover crops for both soil types as sorghum total dry biomass yield for clayey soil fluctuated from 23 to 27 t ha(-1) for control plots, from 25.2 to 30.9 t ha(-1) when faba bean was harvested and from 26.3 to 32.5 t ha(-1) when incorporated, and for sandy soil the yield fluctuated from 18.1 to 22.1 t ha(-1) for control plots, from 22 to 27 t ha(-1) when faba bean was harvested and from 23.1 to 28.1 t ha(-1) when incorporated. The NUE was estimated at 62 kg kg(-1) and 60 kg kg(-1) for clayey and sandy soils respectively. The N recovery fraction was doubled after incorporating faba bean as green manure, reaching large amounts for both soil types
Understanding consumer patterns on meat and dairy products derived from animals fed with locally produced feed
The scope of this study is to clarify the main factors affecting the consumption of foodstuff derived from animal products. For this, we applied a modified version of the health belief model (HBM); trying to quantify the differences on the impact of two food groups on human health. Principal component analysis was applied to highlight essential components influencing participants to consume locally produced animal products. Based on the 'consumers' perceptions, there is a general positive attitude towards agricultural products of animals fed with locally produced feed (LPF). Most respondents trust more LPF, considering them as healthier than imported ones, enhancing their identity. Age and educational level of respondents are characteristics that significantly influence their answers, as younger and higher educated consumers are more interested in adopting good eating habits, while seeking information about the origin of foodstuff. This is promising parameter for enhancing competitiveness of LPF on both local and international context. Copyright © 2022 Inderscience Enterprises Ltd
Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations
Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA
Background. Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods. We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results. In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8–6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions. Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis
Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy
In the general population with COVID-19, the male sex is an established risk factor for mortality, in part due to a more robust immune response to COVID-19 in women. Because patients on kidney function replacement therapy (KFRT) have an impaired immune response, especially kidney transplant recipients due to their use of immunosuppressants, we examined whether the male sex is still a risk factor for mortality among patients on KFRT with COVID-19. From the European Renal Association COVID-19 Database (ERACODA), we examined patients on KFRT with COVID-19 who presented between February 1st, 2020, and April 30th, 2021. 1204 kidney transplant recipients (male 62.0%, mean age 56.4 years) and 3206 dialysis patients (male 61.8%, mean age 67.7 years) were examined. Three-month mortality in kidney transplant recipients was 16.9% in males and 18.6% in females (p = 0.31) and in dialysis patients 27.1% in males and 21.9% in females (p = 0.001). The adjusted HR for the risk of 3-month mortality in males (vs females) was 0.89 (95% CI 65, 1.23, p = 0.49) in kidney transplant recipients and 1.33 (95% CI 1.13, 1.56, p = 0.001) in dialysis patients (p = 0.02). In a fully adjusted model, the aHR for the risk of 3-month mortality in kidney transplant recipients (vs. dialysis patients) was 1.39 (95% CI 1.02, 1.89, p = 0.04) in males and 2.04 (95% CI 1.40, 2.97, p < 0.001) in females (p = 0.02). In patients on KFRT with COVID-19, the male sex is not a risk factor for mortality among kidney transplant recipients but remains a risk factor among dialysis patients. The use of immunosuppressants in kidney transplant recipients, among other factors, may have narrowed the difference in the immune response to COVID-19 between men and women, and therefore reduced the sex difference in COVID-19 mortality risk
Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis
Background: Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods: The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results: Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2-7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions: This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved
Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy
Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy
© 2022, The Author(s).In the general population with COVID-19, the male sex is an established risk factor for mortality, in part due to a more robust immune response to COVID-19 in women. Because patients on kidney function replacement therapy (KFRT) have an impaired immune response, especially kidney transplant recipients due to their use of immunosuppressants, we examined whether the male sex is still a risk factor for mortality among patients on KFRT with COVID-19. From the European Renal Association COVID-19 Database (ERACODA), we examined patients on KFRT with COVID-19 who presented between February 1st, 2020, and April 30th, 2021. 1204 kidney transplant recipients (male 62.0%, mean age 56.4 years) and 3206 dialysis patients (male 61.8%, mean age 67.7 years) were examined. Three-month mortality in kidney transplant recipients was 16.9% in males and 18.6% in females (p = 0.31) and in dialysis patients 27.1% in males and 21.9% in females (p = 0.001). The adjusted HR for the risk of 3-month mortality in males (vs females) was 0.89 (95% CI 65, 1.23, p = 0.49) in kidney transplant recipients and 1.33 (95% CI 1.13, 1.56, p = 0.001) in dialysis patients (pinteraction = 0.02). In a fully adjusted model, the aHR for the risk of 3-month mortality in kidney transplant recipients (vs. dialysis patients) was 1.39 (95% CI 1.02, 1.89, p = 0.04) in males and 2.04 (95% CI 1.40, 2.97, p < 0.001) in females (pinteraction = 0.02). In patients on KFRT with COVID-19, the male sex is not a risk factor for mortality among kidney transplant recipients but remains a risk factor among dialysis patients. The use of immunosuppressants in kidney transplant recipients, among other factors, may have narrowed the difference in the immune response to COVID-19 between men and women, and therefore reduced the sex difference in COVID-19 mortality risk